Nathan Hardy
Director of Finance/CFO presso SANA BIOTECHNOLOGY, INC.
Patrimonio netto: 5 M $ in data 31/03/2024
Posizioni attive di Nathan Hardy
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| SANA BIOTECHNOLOGY, INC. | Director of Finance/CFO | 01/09/2018 | - |
Storia della carriera di Nathan Hardy
Precedenti posizioni note di Nathan Hardy
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| JUNO THERAPEUTICS INC | Director of Finance/CFO | 01/08/2017 | 01/06/2018 |
| AMGEN INC. | Director/Board Member | 01/02/2007 | 01/08/2017 |
| Corporate Officer/Principal | 01/02/2007 | 01/08/2017 |
Formazione di Nathan Hardy
| University of Notre Dame | Masters Business Admin |
| University of Utah | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 6 |
Posizioni
| Director of Finance/CFO | 2 |
| Director/Board Member | 1 |
| Corporate Officer/Principal | 1 |
Settori
| Health Technology | 4 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| SANA BIOTECHNOLOGY, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
- Borsa valori
- Insiders
- Nathan Hardy
- Esperienza
